Efavirenz concentrations and probability of virologic failure and adverse effects in HIV-infected children
This project aimed to assess the pharmacokinetics of efavirenz in HIV-infected children and estimate the probability of virologic failure and adverse effects using US-FDA approved weight-band dosing. A higher proportion of children with a C12 < 1.0 mg/L had viral replication compared to those with a C12 > 1.0 mg/L, and a lower C12 and C24 were associated with a higher odds of viral replication. Our pharmacokinetic model predicted that approximately 15% of children would have a C12 < 1.0 mg/L when receiving US FDA-approved weight-band dosing (<1% for children with a slow metabolizer phenotype) and these children had a 23% risk of viral replication.
For further information please refer to: Efavirenz Concentrations and Probability of HIV Replication in Children